Significance and Use
The Manual Observer-Dependent Assay—The manual quantification of cell and CFU cultures based on observer-dependent criteria or judgment is an extremely tedious and time-consuming task and is significantly impacted by user bias. In order to maintain consistency in data acquisition, pharmacological and drug discovery and development studies utilizing cell- and colony-based assays often require that a single observer count cells and colonies in hundreds, and potentially thousands of cultures. Due to observer fatigue, both accuracy and reproducibility of quantification suffer severely (5). When multiple observers are employed, observer fatigue is reduced, but the accuracy and reproducibility of cell and colony enumeration is still significantly compromised due to observer bias and significant intra- and inter-observer variability (4, 13). Use of quantitative automated image analysis provides data for both the number of colonies as well as the number of cells in each colony. These data can also be used to calculate mean cells per colony. Traditional methods for quantification of colonies by hand counting coupled with an assay for cell number (for example, DNA or mitochondrial) remains a viable method that can be used to calculate the mean number of cells per colony. These traditional methods have the advantage that they are currently less labor intensive and less technically demanding (8, 9). However, the traditional assays do not, provide colony level information (for example, variation and skew), nor do they provide a means for excluding cells that are not part of a colony from the calculation of mean colony size. As a result, the measurement of the mean number of cells per colony that is obtained from these alternative methods may differ when substantial numbers of cells in a sample are not associated with colony formation. By employing state-of-the-art image acquisition, processing and analysis hardware and software, an accurate, precise, robust and automated analysis system is realized.
Areas of Application—Cell and colony enumeration (CFU assay) is becoming particularly important in the manufacture, quality assurance/control (QA/QC), and development of product safety and potency release criteria for cell-based regenerative medicine and cellular therapy. In 2006, the Food and Drug Administration (FDA) released a guidance document foreshadowing the importance of the colony assay in establishing an audit trail for the aforementioned steps of product development in this industry (10). Corroborating this document, the FDA released an additional guidance document in 2009 proposing the potential significance of the colony assay with regard to functional potency of placental and umbilical cord blood-derived stem cells in regenerative medicine and therapeutic applications (11). Since cell source validation and QA/QC comprise approximately 50 % of the manufacturing cost of cellular therapies (12), developing a precise, robust, and cost-effective means for enumerating cells and colonies is vital to sustainability and growth in this industry. The broad areas of use for automated analysis of colony forming unit assays include:
Characterization of a cell source by correlating biological potential and functional potency with CFU formation.
Characterization of the effect of processing steps or biological or physical manipulation (for example, stimuli) on cells or colony formation.
Cell and colony characterization using specific fluorescent and non-fluorescent (differentiation) markers.
Extrapolation of the biological potency (for example, differentiation, proliferative, and so forth) of a larger sample from application of colony forming assay to sub-samples.
Provision of criteria for sub-colony selection of preferred colonies (specific tissue type, proliferation rate, and so forth) for use and/or further expansion.
The Technology (image acquisition, processing, and analysis)—Current standards utilize user input for defining the presence and location of colonies based on visualization of an entire culture surface at low magnification through the eyepieces of a microscope. In this case, the sample may be viewed in transmission light mode (unstained or with a histochemical marker) or fluorescently with a dye or antibody. For this test method, the colony count is the only measurable output parameter. Utilizing a microscope-based imaging system to stitch together high resolution image tiles into a single mosaic image of the entire culture surface and subsequently “clustering” segmented cells using image processing algorithms to delineate colonies, provides a fully automated, accurate, and precise method for characterizing the biological potential and functional potency of the cultured cells. Furthermore, extracted parameters in addition to colony number provide means of further characterization and sub-classification of colony level statistics. These parameters include, but are not limited to, cell/nuclear count, cell/nuclear density, colony morphology (shape and size parameters), secondary marker coverage, effective proliferation rates, and so forth (Fig. A1.2). In addition to Human Connective Tissue Progenitors (CTPs), this test method and technology has been implemented in the cell and colony identification and characterization of several cell and tissue types including: Cartilage Progenitor Cells (Fig. X1.1); Umbilical Cord Blood Hematopoietic Stem Cells (Fig. X1.2); Adipose-derived Stem Cells (Fig. X1.3); and Human Epidermal (Fig. X1.4) and Dermal (Fig. X1.5) Stem Cells.
Benefits of Automated Analysis of CFU Assays—Automated analysis is expected to provide more rapid, reproducible, and precise results in comparison to the manual enumeration of cells and colonies utilizing a microscope, hemocytometer, and so forth. In addition to being highly time and labor intensive and subjective, manual enumeration has been shown to have a significant degree of intra- and inter-observer variability, with coefficients of variation (CV) ranging from 8.1 to 40.0 % and 22.7 to 80 %, respectively. Standard CVs for cell viability assessment and progenitor (colony) type enumeration have been shown to range from 19.4 to 42.9 % and 46.6 to 100 %, respectively (4, 13, 14). In contrast, studies focusing on bacteria, bone marrow-derived stem cells and osteogenic progenitor cells have collectively concluded that automated enumeration provides significantly greater accuracy, precision, and/or speed for counting and sizing cells and colonies, relative to conventional manual methodologies (4-6). Automated methods for enumerating cells and colonies are less biased, less time consuming, less laborious, and provide greater qualitative and quantitative data for intrinsic characteristics of cell and colony type and morphology.
Selection of Cell Culture Surface Area and Optimal Cell Seeding Density—When performing a CFU assay, optimizing the cell culture surface area and cell seeding density is critical to developing methods for generating reliable and reproducible colony- and cell-level data. If seeding density is too low, then the frequency of observed colonies is decreased. This can result in a sampling size that is inadequate to characterize the population of CFUs in the sample. If seeding density is too high, the colonies that are formed may be too closely spaced. Overlapping colony footprints compromise colony counting and characterization. Because the intrinsic range of CFU prevalence in a given cell source may vary widely, in many cases, a trial and error approach to optimizing cell seeding density (or range of densities) that are needed for a given cell source will be necessary. It is important to note that the more heterogeneous the cell source (for example, bone marrow), the more colonies that are needed to accurately represent the stem and progenitor cell constituents. Further, the cell type, effective proliferation rate (EPR) and specific cell culture conditions (for example, media, serum, factors, oxygen tension, and so forth) can impact colony formation. For example, the automated CFU Assay depicted in Fig. A1.2 employs a six-day culture period, two media changes, 20 % oxygen tension, alpha-MEM media (with 25 % fetal bovine serum, ascorbate, dexamethasone and streptomycin),an optimized cell seeding density of 250 000 nucleated cells per cm2 (250 000 cell per 1 mL of cell culture medium) and a cell culture surface area of 22 by 22 mm (dual-chamber Lab-Tek culture slides) (15, 16).
1.1 This test method, provided its limitations are understood, describes a procedure for quantitative measurement of the number and biological characteristics of colonies derived from a stem cell or progenitor population using image analysis.
1.2 This test method is applied in an in vitro laboratory setting.
1.3 This method utilizes: (a) standardized protocols for image capture of cells and colonies derived from in vitro processing of a defined population of starting cells in a defined field of view (FOV), and (b) standardized protocols for image processing and analysis.
1.4 The relevant FOV may be two-dimensional or three-dimensional, depending on the CFU assay system being interrogated.
1.5 The primary unit to be used in the outcome of analysis is the number of colonies present in the FOV. In addition, the characteristics and sub-classification of individual colonies and cells within the FOV may also be evaluated, based on extant morphological features, distributional properties, or properties elicited using secondary markers (for example, staining or labeling methods).
1.6 Imaging methods require that images of the relevant FOV be captured at sufficient resolution to enable detection and characterization of individual cells and over a FOV that is sufficient to detect, discriminate between, and characterize colonies as complete objects for assessment.
1.7 Image processing procedures applicable to two- and three-dimensional data sets are used to identify cells or colonies as discreet objects within the FOV. Imaging methods may be optimized for multiple cell types and cell features using analytical tools for segmentation and clustering to define groups of cells related to each other by proximity or morphology in a manner that is indicative of a shared lineage relationship (that is, clonal expansion of a single founding stem cell or progenitor).
1.8 The characteristics of individual colony objects (cells per colony, cell density, cell size, cell distribution, cell heterogeneity, cell genotype or phenotype, and the pattern, distribution and intensity of expression of secondary markers) are informative of differences in underlying biological properties of the clonal progeny.
1.9 Under appropriately controlled experimental conditions, differences between colonies can be informative of the biological properties and underlying heterogeneity of colony founding cells (CFUs) within a starting population.
1.10 Cell and colony area/volume, number, and so forth may be expressed as a function of cell culture area (square millimetres), or initial cell suspension volume (millilitres).
1.11 Sequential imaging of the FOV using two or more optical methods may be valuable in accumulating quantitative information regarding individual cells or colony objects in the sample. In addition, repeated imaging of the same sample will be necessary in the setting of process tracking and validation. Therefore, this test method requires a means of reproducible identification of the location of cells and colonies (centroids) within the FOV area/volume using a defined coordinate system.
1.12 To achieve a sufficiently large field-of-view (FOV), images of sufficient resolution may be captured as multiple image fields/tiles at high magnification and then combined together to form a mosaic representing the entire cell culture area.
1.13 Cells and tissues commonly used in tissue engineering, regenerative medicine, and cellular therapy are routinely assayed and analyzed to define the number, prevalence, biological features, and biological potential of the original stem cell and progenitor population(s).
1.13.1 Common applicable cell types and cell sources include, but are not limited to: mammalian stem and progenitor cells; adult-derived cells (for example, blood, bone marrow, skin, fat, muscle, mucosa) cells, fetal-derived cells (for example, cord blood, placental/cord, amniotic fluid); embryonic stem cells (ESC) (that is, derived from inner cell mass of blastocysts); induced pluripotency cells (iPS) (for example, reprogrammed adult cells); culture expanded cells; and terminally differentiated cells of a specific type of tissue.
1.13.2 Common applicable examples of mature differentiated phenotypes which are relevant to detection of differentiation within and among clonal colonies include: hematopoietic phenotypes (erythrocytes, lymphocytes, neutrophiles, eosinophiles, basophiles, monocytes, macrophages, and so forth), mesenchymal phenotypes (oteoblasts, chondrocytes, adipocytes, and so forth), and other tissues (hepatocytes, neurons, endothelial cells, keratinocyte, pancreatic islets, and so forth).
1.14 The number of stem cells and progenitor cells in various tissues can be assayed in vitro by liberating the cells from the tissues using methods that preserve the viability and biological potential of the underlying stem cell and/or progenitor population, and placing the tissue-derived cells in an in vitro environment that results in efficient activation and proliferation of stem and progenitor cells as clonal colonies. The true number of stem cells and progenitors (true colony forming units (tCFU)) can thereby be estimated on the basis of the number of colony-forming units observed (observed colony forming units (oCFU)) to have formed (1-3) (Fig. A1.1). The prevalence of stem cells and/or progenitors can be estimated on the basis of the number of observed colony-forming units (oCFU) detected, divided by the number of total cells assayed.
1.15 The automated image acquisition and analysis approach (described herein) to cell and colony enumeration has been validated and found to provide superior accuracy and precision when compared to the current “gold standard” of manual observer defined visual cell and colony counting under a brightfield or fluorescent microscope with or without a hemocytomer (4), reducing both intra- and inter-observer variation. Several groups have attempted to automate this and/or similar processes in the past (5, 6). Recent reports further demonstrate the capability of extracting qualitative and quantitative data for colonies of various cell types at the cellular and even nuclear level (4, 7).
1.16 Advances in software and hardware now broadly enable systematic automated analytical approaches. This evolving technology creates the need for general agreement on units of measurement, nomenclature, process definitions, and analytical interpretation as presented in this test method.
1.17 Standardized methods for automated CFU analysis open opportunities to enhance the value and utility of CFU assays in several scientific and commercial domains:
1.17.1 Standardized methods for automated CFU analysis open opportunities to advance the specificity of CFU analysis methods though optimization of generalizable protocols and quantitative metrics for specific cell types and CFU assay systems which can be applied uniformly between disparate laboratories.
1.17.2 Standardized methods for automated CFU analysis open opportunities to reduce the cost of colony analysis in all aspects of biological sciences by increasing throughput and reducing work flow demands.
1.17.3 Standardized methods for automated CFU analysis open opportunities to improve the sensitivity and specificity of experimental systems seeking to detect the effects of in vitro conditions, biological stimuli, biomaterials and in vitro processing steps on the attachment, migration, proliferation, differentiation, and survival of stem cells and progenitors.
1.18 Limitations are described as follows:
1.18.1 Colony IdentificationCell Source/Colony Type/Marker Variability—Stem cells and progenitors from various tissue sources and in different in vitro environments will manifest different biological features. Therefore, the specific means to detect cells or nuclei and secondary markers utilized and the implementation of their respective staining protocols will differ depending on the CFU assay system, cell type(s) and markers being interrogated. Optimized protocols for image capture and image analysis to detect cells and colonies, to define colony objects and to characterize colony objects will vary depending on the cell source being utilized and CFU system being used. These protocols will require independent optimization, characterization and validation in each application. However, once defined, these can be generalized between labs and across clinical and research domains.
1.18.2 Instrumentation Induced Variability in Image Capture—Choice of image acquisition components described above may adversely affect segmentation of cells and subsequent colony identification if not properly addressed. For example, use of a mercury bulb rather than a fiber-optic fluorescent light source or the general misalignment of optics could produce uneven illumination or vignetting of tiles images comprising the primary large FOV image. This may be corrected by applying background subtraction routines to each tile in a large FOV image prior to tile stitching.
1.18.3 CFU Assay System Associated Variation in Imaging Artifacts—In addition to the presentation of colony objects with unique features that must be utilized to define colony identification, each image from each CFU system may present non-cell and non-colony artifacts (for example, cell debris, lint, glass aberrations, reflections, autofluorescence, and so forth) that may confound the detection of cells and colonies if not identified and managed.
1.18.4 Image Capture Methods and Quality Control Variation—Variation in image quality will significantly affect the precision and reproducibility of image analysis methods. Variation in focus, illumination, tile registration, exposure time, quenching, and emission spectral bleeding, are all important potential limitations or threats to image quality and reproducibility.
1.19 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.
1.20 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
automated cell and colony enumeration; automated colony forming unit assays; biological potential; cells; cell-based assays; cell source validation; cell therapies; CFU; colonies; colony area; colony cell density; colony morphology; colony size; counting; differentiation markers; drug developments; drug discoveries; FDA; image acquisition; image analysis; image processing; pharmaceuticals; progenitor cells; proliferation rates; quality control; quality assurance; QA/QC; stem cells;
ICS Number Code 07.100.01 (Microbiology in general); 11.100.10 (In vitro diagnostic test systems)
ASTM International is a member of CrossRef.
Citing ASTM Standards
[Back to Top]